The transition from film-screen to digital mammography increases the cancer detection rateand recall rate for at least two years, while positive predictive value tends to decrease, according to a study published online July 25 in Radiology.

Michigan State University (MSU) will work with Cardinal Health to open a new radio-pharmacy on campus, allowing access to nuclear imaging agents created at MSUs medical cyclotron, according to a press release from MSU.

The National Institute for Health and Clinical Excellence (NICE) in the U.K. has recommended bivalirudin (Angiox in the EU/Angiomax in the U.S., The Medicines Company) in combination with aspirin and clopidogrel, for the treatment of STEMI patients undergoing PCI.

Researchers have developed tissue-engineered intervertebral disc (IVD) implants which have been successfully implanted in rodents spines, according to study findings published Aug. 1 in the Proceedings of the National Academy of Sciences.

The FDA is seeking public comment on factors affecting the reprocessing of reusable medical devices, according to a July 28 notice published in the Federal Register. According to the article, the administration is considering reprocessing quality, device design as it relates to reprocessing, reprocessing methodologies, validation methodologies and healthcare facility best practices.

PET imaging is showing a 7 percent average annual growth rate from 2008 to 2010, which is a decrease from the average annual rate of 10.4 percent from 2005 to 2008, according to IMV's research report, 2011 PET Market Summary Report.

The American College of Radiology and the Society of Breast Imaging have issued a statement in response to the controversial study published July 28 in the British Medical Journal (BMJ), which claimed there is no evidence that mammography screening served a direct role in reducing breast cancer deaths in European countries where screening has been implemented.

Genzyme has submitted a marketing authorization application to the European Medicines Agency (EMA) in hopes to gain approval for its 200 mg weekly dose of mipomersen, an apo-B synthesis inhibitor indicated to treat hypercholesterolemia and lower LDL cholesterol levels, which is co-developed with Isis Pharmaceuticals.